-
Genetic variants of CYP2C9/VKORC1 (显示 VKORC1 蛋白) and age are significant determinants of the maintenance dose of warfarin in patients with atrial fibrillation/valve replacement.
-
CYP2C9*3 polymorphism genotype and allele frequency were not statistically different between the case and control Ankylosing Spondylitis groups (P>0.05). the efficacy of NSAID in treatment of AS and COX-2 gene -1290A/G and -1195G/A polymorphism were associated (all P<0.05), but it is not associated with CYP2C9 *3 polymorphism (all P>0.05).
-
polymorphisms c.98T>C in the UGT1A9 (显示 UGT1A9 蛋白) and c.1075A>C in the CYP2C9 genes did not affect the pharmacokinetic profile of propofol
-
Possession of CYP2C9*2 and/or CYP2C9*3 allele variants is associated with lower time of international normalized ratio (INR (显示 INSR 蛋白)) in the therapeutic range (TTR (显示 TTR 蛋白)) values and warfarin dose variations in aortic valve replacement patients, the latter affected also by VKORC1 (显示 VKORC1 蛋白) c.-1693G>A polymorphism
-
Three SNPs (CYP2C9 *2, *3 and VKORC1 (显示 VKORC1 蛋白) c.-1639G > A) were genotyped by electrochemical detection using a sandwich-type format that included a 3' short thiol capture probe and a 5' ferrocene-labeled signal probe.
-
This study was aimed to describe the distribution of CYP2C9 and CYP2C19 (显示 CYP2C19 蛋白) alleles and haplotypes in four Mestizo populations from Western Mexico. Frequencies ranged from 2.2-3.0% and 4.8-8.9% for CYP2C9*3 and CYP2C9*2 alleles, respectively, and 5.4-12.0% for CYP2C19 (显示 CYP2C19 蛋白)*2, whereas the CYP2C19 (显示 CYP2C19 蛋白)*3 allele was not found.
-
CYP2C9 IVS8-109 T carriers showed significantly higher dose-corrected phenoytoin blood concentrations and this allele was found in a higher frequency in epileptic patients with supratherapeutic phenytoin levels.
-
Med25 (显示 MED9 蛋白), a variable member of the Mediator complex, is a coactivator of ligand-activated ERalpha (显示 ESR1 蛋白) that interacts with ERalpha (显示 ESR1 蛋白) through its C-terminal LXXLL motif after BPA (显示 DST 蛋白) exposure, and is functionally involved in BPA (显示 DST 蛋白)-induced transcriptional regulation of CYP2C9 expression and enzyme activity.
-
We conclude that CYP2C9/2C19 genotype is not relevant for variability in valproic acid exposure.
-
Our results show that anticoagulated patients have a high risk of adverse events if they are carriers of 1 or more genetic polymorphisms in the VKORC1 (显示 VKORC1 蛋白) (rs9923231) and CYP2C9 (rs1799853 and rs1057910) genes.
